A French company has developed a solution for the post-processing of cardiac MRI (Magnetic Resonance Imaging) allowing physicians to diagnose cardiac pathologies. Based on artificial intelligence and deep learning algorithms, the solution provides a real decision making aid for cardiologists, radiologists. The company is looking for cooperation with public or private health institutions that practice cardiac MRI under a license agreement.
A French company has developed a solution for the post-processing of cardiac MRI allowing to read images in DICOM format (digital imaging and communications in medicine), to analyze MRI examinations and to help the physician to diagnose cardiac pathologies. Several modules are integrated such as cardiac function, strain, 2D aortic flow, compliance, late enhancement and first pass or T1, T2 and T2* mapping. The medical device offered by the French company is a post processing software for cardiac MRI based on artificial intelligence (AI) and deep learning algorithms. The main objective of this innovative medical device enables to detect the different areas of the heart to quantify the clinical parameters and to help with cardiac diagnosis. This stand-alone software has 4 modules integrating the main sequences necessary for the physician to perform his diagnosis such as in Cine (Cardiac function and Strain), Late enhancement, First Pass, Mapping (T1, T2, T3), Aortic Flow and Compliance. There different modules allow to highlight pathologies such as myocardial diseases, strokes and tumors. One of the main challenges for today's physicians is to make the best diagnosis in the shortest time, which is why the software includes AI algorithms. The system allows doctor’s working time to be reduced by a factor of 10 and it solves a major problem encountered by practitioners to correct the contours which are drawn automatically and inaccurately. This software is dedicated to cardiologists to diagnose the cardiac pathologies of their patients and to produce a report. It is also dedicated to radiologists with experience or training in cardiac imaging. The device is CE marked according to the European classification system and FDA clearance is under progress. The company is ISO 13485 certified. QIR is based on Deep Learning algorithms, and include the first algorithm to offer an AI-based anatomical guarantee, which implies that the contour is correctly positioned on the heart and therefore reduces the risk of misdetection. In addition, the software integrates the first false positive detection algorithm for myocardial infarction, which allows the physician to save considerable time. The software was designed to be easy to use and quick to master, usable on an entry-level computer and compatible with all MRI manufacturers. Available in 6 languages, it is adaptable to the international context in which the industry operates. The company is looking for cooperation with public or private health institutions that practice cardiac MRI under license agreements.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
Type of partners sought : Healthcare public or private companies that practice cardiac MRI and wish to optimize their imaging areas, include an innovative solution with AI or improve patient care. Once a license is acquired, the company will take care of the installation and integration of the solution in the environment. Training sessions will be held to teach the user how to use the software in the environment. A regular follow-up will be set up to follow the evolution of the doctors in their practices.
Stage of Development:
Already on the market
Secret Know-how,Trade Marks,Copyright